\-\ Texto\\:\\ \ \(0\)\
\-\ urine\\ values\\:\ \(0\)\
\-\ \\ \\ normetanephrine\\ 24h\\:\\ 406\\ ug\\/24hr\\ \\ \\(53\\-310\\ ug\\/24hr\\)\ \(0\)\
\-\ \\ \\ metanephrine\\ 24h\\:\\ \\ \\ \\ 594\\ ug\\/24hr\\ \\ \\(95\\-475\\ ug\\/24hr\\)\ \(0\)\
\-\ surgical\\ resection\\ is\\ the\\ standard\\ curative\\ modality\\.\\ if\\ the\\ primary\\ tumor\\ is\\ localized\\ to\\ the\\ adrenal\\ gland\\ and\\ is\\ benign\\,\\ then\\ survival\\ is\\ that\\ of\\ the\\ normal\\ age\\-matched\\ population\\.\\ in\\ patients\\ with\\ unresectable\\,\\ recurrent\\,\\ or\\ metastatic\\ disease\\ long\\-term\\ survival\\ is\\ possible\\.\\ however\\,\\ the\\ overall\\ 5\\-year\\ survival\\ is\\ less\\ than\\ 50\\%\\.\\ pharmacologic\\ treatment\\ of\\ the\\ catecholamine\\ excess\\ is\\ mandatory\\ and\\ surgery\\,\\ radiation\\ therapy\\,\\ or\\ chemotherapy\\ may\\ provide\\ palliative\\ benefit\\.\ \(0\)\
\-\ dose\\:\\ 10\\.5\\ mci\\ iodine\\-123\\ mibg\\,\\ iv\\.\ \(0\)\
\-\ procedure\\:\\ after\\ pretreatment\\ with\\ sski\\ solution\\ to\\ block\\ uptake\\ in\\ the\\ thyroid\\ gland\\,\\ radiotracer\\ was\\ injected\\.\\ \\ 24\\ hour\\ delayed\\ planar\\ and\\ single\\ photon\\ emission\\ computed\\ tomography\\ \\(spect\\)\\ of\\ the\\ chest\\,\\ abdomen\\ and\\ pelvis\\ were\\ obtained\\.\ \(0\)\
\-\ findings\\:\\ \\ the\\ planar\\ images\\ demonstrated\\ normal\\ distribution\\ of\\ radiotracer\\ activity\\ and\\ no\\ uptake\\ identified\\ in\\ the\\ bilateral\\ adrenal\\ regions\\ \\(not\\ shown\\)\\.\\ \\ the\\ spect\\ images\\ demonstrate\\ in\\ three\\ orthogonal\\ tomographic\\ planes\\,\\ focal\\ uptake\\ in\\ the\\ bilateral\\ upper\\ retroperitoneal\\/adrenal\\ regions\\.\\ \\ there\\ are\\ no\\ other\\ areas\\ of\\ abnormal\\ radiotracer\\ accumulation\\.\ \(0\)\
\-\ bilateral\\ pheochromocytoma\ \(0\)\
\-\ pheochromocytoma\\ \ \(6\)\
\-\ neuroblastoma\ \(81\)\
\-\ ganglioneuro\\(blasto\\)ma\ \(0\)\
\-\ \\(ddx\\ for\\ imaging\\ findings\\ only\\)\ \(0\)\
\-\ 82\\ y\\/o\\ white\\ female\\ with\\ anxiety\\ attacks\\ and\\ labile\\ hypertension\\.\\ \\ \\ laboratory\\ values\\ consistent\\ with\\ pheochromocytoma\\.\\ \\ please\\ evaluate\\ with\\ nuclear\\ scintigraphy\ \(0\)\
\-\ see\\ factoid\\.\ \(59\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ ug\\/24hr\\:\\ 0\\.13153637641144214\ \(0\)\
\-\ pheochromocytoma\\:\\ 0\\.0670406666958968\ \(0\)\
\-\ 24h\\:\\ 0\\.06248506992144444\ \(0\)\
\-\ survival\\:\\ 0\\.05564467918262233\ \(0\)\
\-\ radiotracer\\:\\ 0\\.0484275872874194\ \(0\)\
\-\ spect\\:\\ 0\\.04599209885050485\ \(0\)\
\-\ planar\\:\\ 0\\.044999367497530494\ \(0\)\
\-\ uptake\\:\\ 0\\.04123461649426169\ \(0\)\
\-\ 53\\-310\\:\\ 0\\.0356903579917672\ \(0\)\
\-\ age\\-matched\\:\\ 0\\.0356903579917672\ \(0\)\
\-\ iodine\\-123\\:\\ 0\\.0356903579917672\ \(0\)\
\-\ sski\\:\\ 0\\.0356903579917672\ \(0\)\
\-\ retroperitoneal\\/adrenal\\:\\ 0\\.0356903579917672\ \(0\)\
\-\ ganglioneuro\\:\\ 0\\.0356903579917672\ \(0\)\
\-\ blasto\\:\\ 0\\.0356903579917672\ \(0\)\
\-\ labile\\:\\ 0\\.0356903579917672\ \(0\)\
\-\ adrenal\\:\\ 0\\.03503548222052112\ \(0\)\
\-\ values\\:\\ 0\\.034592903981348136\ \(0\)\
\-\ 406\\:\\ 0\\.032884094102860535\ \(0\)\
\-\ 594\\:\\ 0\\.032884094102860535\ \(0\)\
\-\ 95\\-475\\:\\ 0\\.032884094102860535\ \(0\)\
\-\ catecholamine\\:\\ 0\\.032884094102860535\ \(0\)\
\-\ regions\\:\\ 0\\.03166189186662404\ \(0\)\
\-\ normetanephrine\\:\\ 0\\.030077830213953875\ \(0\)\
\-\ mandatory\\:\\ 0\\.030077830213953875\ \(0\)\
\-\ pretreatment\\:\\ 0\\.030077830213953875\ \(0\)\
\-\ gland\\:\\ 0\\.02946857239994064\ \(0\)\
\-\ metanephrine\\:\\ 0\\.029174415026446954\ \(0\)\
\-\ unresectable\\:\\ 0\\.02843627107181556\ \(0\)\
\-\ mibg\\:\\ 0\\.02843627107181556\ \(0\)\
\-\ pharmacologic\\:\\ 0\\.02781217925065257\ \(0\)\
\-\ photon\\:\\ 0\\.02781217925065257\ \(0\)\
\-\ \\:\\:\\ 0\\.02745606840463154\ \(0\)\
\-\ 10\\.5\\:\\ 0\\.02679471192967724\ \(0\)\
\-\ orthogonal\\:\\ 0\\.02679471192967724\ \(0\)\
\-\ solution\\:\\ 0\\.025982279964243432\ \(0\)\
\-\ attacks\\:\\ 0\\.025982279964243432\ \(0\)\
\-\ emission\\:\\ 0\\.025630007182908896\ \(0\)\
\-\ 5\\-year\\:\\ 0\\.025305947637671907\ \(0\)\
\-\ bilateral\\:\\ 0\\.02518806958681511\ \(0\)\
\-\ tomographic\\:\\ 0\\.023769552408097402\ \(0\)\
\-\ ma\\:\\ 0\\.023769552408097402\ \(0\)\
\-\ curative\\:\\ 0\\.023176016075336772\ \(0\)\
\-\ excess\\:\\ 0\\.023176016075336772\ \(0\)\
\-\ anxiety\\:\\ 0\\.02265847206112671\ \(0\)\
\-\ mci\\:\\ 0\\.022499683748765247\ \(0\)\
\-\ block\\:\\ 0\\.022346888898632265\ \(0\)\
\-\ injected\\:\\ 0\\.02141359473421189\ \(0\)\
\-\ 82\\:\\ 0\\.02141359473421189\ \(0\)\
\-\ palliative\\:\\ 0\\.021071257130859406\ \(0\)\
\-\ benefit\\:\\ 0\\.020655653268267977\ \(0\)\
\-\ scintigraphy\\:\\ 0\\.020102715879580728\ \(0\)\
\-\ planes\\:\\ 0\\.019852208172220047\ \(0\)\
\-\ provide\\:\\ 0\\.019393387583932584\ \(0\)\
\-\ long\\-term\\:\\ 0\\.019114064217588655\ \(0\)\
\-\ modality\\:\\ 0\\.018981311898467232\ \(0\)\
\-\ hour\\:\\ 0\\.018916533188562616\ \(0\)\
\-\ tomography\\:\\ 0\\.018489972396425663\ \(0\)\
\-\ accumulation\\:\\ 0\\.018432544724393454\ \(0\)\
\-\ computed\\:\\ 0\\.018264993241952746\ \(0\)\
\-\ ddx\\:\\ 0\\.018264993241952746\ \(0\)\
\-\ dose\\:\\ 0\\.0181041012231288\ \(0\)\
\-\ population\\:\\ 0\\.01805186071772027\ \(0\)\
\-\ nuclear\\:\\ 0\\.017849389379361317\ \(0\)\
\-\ standard\\:\\ 0\\.017703915657798306\ \(0\)\
\-\ \\(\\:\\ 0\\.017547248410782038\ \(0\)\
\-\ \\)\\:\\ 0\\.017332899403562068\ \(0\)\
\-\ neuroblastoma\\:\\ 0\\.017296451990674068\ \(0\)\
\-\ overall\\:\\ 0\\.017211215516188916\ \(0\)\
\-\ localized\\:\\ 0\\.016848413254287348\ \(0\)\
\-\ urine\\:\\ 0\\.0166970467276816\ \(0\)\
\-\ is\\:\\ 0\\.015935366189040807\ \(0\)\
\-\ distribution\\:\\ 0\\.015569656374050597\ \(0\)\
\-\ please\\:\\ 0\\.015350760741377416\ \(0\)\
\-\ findings\\:\\ 0\\.01472742458129522\ \(0\)\
\-\ recurrent\\:\\ 0\\.01459932093572906\ \(0\)\
\-\ procedure\\:\\ 0\\.014490188101767405\ \(0\)\
\-\ thyroid\\:\\ 0\\.014179402611031218\ \(0\)\
\-\ delayed\\:\\ 0\\.014080892082045264\ \(0\)\
\-\ single\\:\\ 0\\.014022916155831707\ \(0\)\
\-\ evaluate\\:\\ 0\\.013984721693348473\ \(0\)\
\-\ shown\\:\\ 0\\.013872253822469625\ \(0\)\
\-\ hypertension\\:\\ 0\\.013638789685425862\ \(0\)\
\-\ 24\\:\\ 0\\.013451242836542306\ \(0\)\
\-\ images\\:\\ 0\\.013273391837646592\ \(0\)\
\-\ 50\\:\\ 0\\.013161935290055889\ \(0\)\
\-\ activity\\:\\ 0\\.012979945865512302\ \(0\)\
\-\ laboratory\\:\\ 0\\.012749359254469904\ \(0\)\
\-\ iv\\:\\ 0\\.012625202175955846\ \(0\)\
\-\ pelvis\\:\\ 0\\.012571220269601736\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.01240059022324237\ \(0\)\
\-\ identified\\:\\ 0\\.012362214741645026\ \(0\)\
\-\ then\\:\\ 0\\.012311606795231134\ \(0\)\
\-\ obtained\\:\\ 0\\.012299053039448752\ \(0\)\
\-\ factoid\\:\\ 0\\.012127269204915534\ \(0\)\
\-\ benign\\:\\ 0\\.011939475170174905\ \(0\)\
\-\ less\\:\\ 0\\.011716356292804382\ \(0\)\
\-\ three\\:\\ 0\\.011662446268610974\ \(0\)\
\-\ possible\\:\\ 0\\.011651749874024583\ \(0\)\
\-\ areas\\:\\ 0\\.011641081664963833\ \(0\)\
\-\ white\\:\\ 0\\.011474106124340152\ \(0\)\
\-\ radiation\\:\\ 0\\.01135324392535359\ \(0\)\
\-\ \\,\\:\\ 0\\.010959921680861837\ \(0\)\
\-\ normal\\:\\ 0\\.01084706440970932\ \(0\)\
\-\ resection\\:\\ 0\\.010789132208583881\ \(0\)\
\-\ only\\:\\ 0\\.01040247635014144\ \(0\)\
\-\ see\\:\\ 0\\.010324766037363516\ \(0\)\
\-\ primary\\:\\ 0\\.010248519282978529\ \(0\)\
\-\ abdomen\\:\\ 0\\.010248519282978529\ \(0\)\
\-\ demonstrated\\:\\ 0\\.010151497904684078\ \(0\)\
\-\ focal\\:\\ 0\\.009880540907442923\ \(0\)\
\-\ abnormal\\:\\ 0\\.009866770203704094\ \(0\)\
\-\ however\\:\\ 0\\.009633069051000285\ \(0\)\
\-\ y\\/o\\:\\ 0\\.009581494047852796\ \(0\)\
\-\ if\\:\\ 0\\.009387625237978281\ \(0\)\
\-\ therapy\\:\\ 0\\.009249557879516652\ \(0\)\
\-\ than\\:\\ 0\\.009064975121126615\ \(0\)\
\-\ patients\\:\\ 0\\.00895374331727136\ \(0\)\
\-\ metastatic\\:\\ 0\\.008708944953911297\ \(0\)\
\-\ in\\:\\ 0\\.00853030830243431\ \(0\)\
\-\ consistent\\:\\ 0\\.00848298894263645\ \(0\)\
\-\ surgery\\:\\ 0\\.00840080592858411\ \(0\)\
\-\ upper\\:\\ 0\\.008348504070318698\ \(0\)\
\-\ chest\\:\\ 0\\.008278255060961614\ \(0\)\
\-\ or\\:\\ 0\\.008109495943025971\ \(0\)\
\-\ imaging\\:\\ 0\\.008105562042330375\ \(0\)\
\-\ \\%\\:\\ 0\\.008070125641076955\ \(0\)\
\-\ tumor\\:\\ 0\\.008065717820286686\ \(0\)\
\-\ other\\:\\ 0\\.00797424513644716\ \(0\)\
\-\ demonstrate\\:\\ 0\\.007961344701753201\ \(0\)\
\-\ were\\:\\ 0\\.00785541026999968\ \(0\)\
\-\ may\\:\\ 0\\.007588373963150299\ \(0\)\
\-\ surgical\\:\\ 0\\.007272152915997788\ \(0\)\
\-\ after\\:\\ 0\\.007157899605705273\ \(0\)\
\-\ female\\:\\ 0\\.007112389762946695\ \(0\)\
\-\ treatment\\:\\ 0\\.00700249781214934\ \(0\)\
\-\ no\\:\\ 0\\.0069671591150105424\ \(0\)\
\-\ the\\:\\ 0\\.006716564439042549\ \(0\)\
\-\ that\\:\\ 0\\.005975630479995236\ \(0\)\
\-\ disease\\:\\ 0\\.005654807859172891\ \(0\)\
\-\ there\\:\\ 0\\.0051486459775910475\ \(0\)\
\-\ not\\:\\ 0\\.004999265877497714\ \(0\)\
\-\ are\\:\\ 0\\.004716088552751424\ \(0\)\
\-\ and\\:\\ 0\\.004372688398353484\ \(0\)\
\-\ was\\:\\ 0\\.004001123571715331\ \(0\)\
\-\ to\\:\\ 0\\.00345804136391082\ \(0\)\
\-\ for\\:\\ 0\\.002951854852804515\ \(0\)\
\-\ with\\:\\ 0\\.002368505588864165\ \(0\)\
\-\ of\\:\\ 0\\.0023583765343722354\ \(0\)\
\-\ \\.\\:\\ 0\\.0020121194549103153\ \(0\)\
